Potential pharmacological agents for COVID-19

Anita Kotwani, Sumanth Gandra

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


A novel coronavirus disease 2019 (COVID-19) infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) first emerged in December 2019 in Wuhan, China, has become a global pandemic. Currently, the management of COVID-19 infection is mainly supportive. Several clinical trials worldwide are evaluating several drugs approved for other indications, as well as multiple investigational agents for the treatment and prevention of COVID-19. Here, we give a brief overview of pharmacological agents and other therapies which are under investigation as treatment options or adjunctive agents for patients infected with COVID-19 and for chemoprophylaxis for the prevention of COVID-19 infection. At the time of writing this commentary, there is no peer-reviewed published evidence from randomized clinical trials of any pharmacological agents improving outcomes in COVID-19 patients. However, it was reported that remdesivir an investigational antiviral agent hastens clinical recovery, but a study is yet to be published in peer-reviewed medical journal.

Original languageEnglish
Pages (from-to)S112-S116
JournalIndian journal of public health
StatePublished - Jun 1 2020


  • Adjunctive therapy
  • coronavirus disease 2019
  • investigational antiviral agents
  • potential pharmacological agents
  • severe acute respiratory syndrome coronavirus 2


Dive into the research topics of 'Potential pharmacological agents for COVID-19'. Together they form a unique fingerprint.

Cite this